Minimal Residual Disease in Prostate Cancer Patients After Primary Treatment: Theoretical Considerations, Evidence and Possible Use in Clinical Management

Overview

Journal Biol Res

Specialty Biology

Date 2018 Sep 6

PMID 30180883

Citations 7

Authors

Nigel P Murray

Affiliations

Soon will be listed here.

Abstract

Minimal residual disease is that not detected by conventional imaging studies and clinically the patient remains disease free. However, with time these dormant cells will awaken and disease progression occurs, resulting in clinically and radiological detectable metastatic disease. This review addresses the concept of tumor cell dissemination from the primary tumor, the micrometastatic niche and tumor cell survival and finally the clinical utility of detecting and characterizing these tumor cells in order to guide management decisions in treating patients with prostate cancer.

Citing Articles

Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.

Roy S, Malone S, Wing K, Chowdhury S, Kishan A, Sun Y JAMA Netw Open. 2024; 7(10):e2439434.

PMID: 39405060 PMC: 11581638. DOI: 10.1001/jamanetworkopen.2024.39434.

Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase.

Liu R, Su S, Xing J, Liu K, Zhao Y, Stangis M J Exp Clin Cancer Res. 2023; 42(1):264.

PMID: 37821954 PMC: 10566127. DOI: 10.1186/s13046-023-02849-0.

Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.

Kish E, Gamallat Y, Choudhry M, Ghosh S, Seyedi S, Bismar T Int J Mol Sci. 2023; 24(5).

PMID: 36901698 PMC: 10001614. DOI: 10.3390/ijms24054260.

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.

Lokhande L, Kuci Emruli V, Eskelund C, Kolstad A, Hutchings M, Raty R Cancer Rep (Hoboken). 2021; 5(7):e1524.

PMID: 34319003 PMC: 9327662. DOI: 10.1002/cnr2.1524.

Impact of prostate focused alignment on planned pelvic lymph node dose.

Kilian-Meneghin J, Ma T, Kumaraswamy L J Appl Clin Med Phys. 2021; 22(7):27-35.

PMID: 34231945 PMC: 8292696. DOI: 10.1002/acm2.13092.

References

Friedlander T, Ngo V, Dong H, Premasekharan G, Weinberg V, Doty S . Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2013; 134(10):2284-93. DOI: 10.1002/ijc.28561. View

McDonald D, Baluk P . Significance of blood vessel leakiness in cancer. Cancer Res. 2002; 62(18):5381-5. View

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

Weckermann D, Wawroschek F, Krawczak G, Haude K, Harzmann R . Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?. Urol Res. 2000; 27(5):285-90. View

Mitchell M, King M . Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013; 3:44. PMC: 3587800. DOI: 10.3389/fonc.2013.00044. View

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S . A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. Cancer Res. 2017; 78(1):129-142. DOI: 10.1158/0008-5472.CAN-16-3507. View

Mordant P, Loriot Y, Lahon B, Castier Y, Leseche G, Soria J . Minimal residual disease in solid neoplasia: New frontier or red-herring?. Cancer Treat Rev. 2011; 38(2):101-10. DOI: 10.1016/j.ctrv.2011.04.014. View

Murant S, Handley J, Stower M, Reid N, Cussenot O, Maitland N . Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer. 1997; 33(2):263-71. DOI: 10.1016/s0959-8049(96)00418-2. View

Schmidmaier R, Baumann P . ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008; 15(10):978-90. DOI: 10.2174/092986708784049667. View

10.

Rischpler C, Beck T, Okamoto S, Schlitter A, Knorr K, Schwaiger M . Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. J Nucl Med. 2018; 59(9):1406-1411. DOI: 10.2967/jnumed.117.204677. View

11.

Tsumura H, Satoh T, Ishiyama H, Tabata K, Takenaka K, Sekiguchi A . Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. Int J Mol Sci. 2017; 18(1). PMC: 5297762. DOI: 10.3390/ijms18010128. View

12.

Jung Y, Decker A, Wang J, Lee E, Kana L, Yumoto K . Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget. 2016; 7(18):25698-711. PMC: 5041937. DOI: 10.18632/oncotarget.8365. View

13.

Quesenberry P, Becker P . Stem cell homing: rolling, crawling, and nesting. Proc Natl Acad Sci U S A. 1998; 95(26):15155-7. PMC: 33927. DOI: 10.1073/pnas.95.26.15155. View

14.

Friedl P, Wolf K . Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev. 2009; 28(1-2):129-35. DOI: 10.1007/s10555-008-9174-3. View

15.

Graff J, Gabrielson E, Fujii H, Baylin S, Herman J . Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem. 2000; 275(4):2727-32. DOI: 10.1074/jbc.275.4.2727. View

16.

Murray N, Reyes E, Fuentealba C, Jacob O, Orellana N . Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence. Asian Pac J Cancer Prev. 2015; 16(15):6615-9. DOI: 10.7314/apjcp.2015.16.15.6615. View

17.

Ma X, Xiao Z, Li X, Wang F, Zhang J, Zhou R . Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol. 2014; 35(6):5551-60. DOI: 10.1007/s13277-014-1731-5. View

18.

Hashizume H, Baluk P, Morikawa S, McLean J, Thurston G, Roberge S . Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156(4):1363-80. PMC: 1876882. DOI: 10.1016/S0002-9440(10)65006-7. View

19.

Taichman R, Patel L, Bedenis R, Wang J, Weidner S, Schumann T . GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One. 2013; 8(4):e61873. PMC: 3634826. DOI: 10.1371/journal.pone.0061873. View

20.

Fidler I . Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 1970; 45(4):773-82. View